Oxidative Stress and Reduced Antioxidative Status, along with Endothelial Dysfunction in Acromegaly

Abstract

Acromegaly is characterized by high cardiovascular morbidity and mortality. Oxidative stress and endothelial dysfunction are underlying mechanisms of atherosclerosis.The aim of this study was to evaluate the blood redox status and endothelial function by means of nitric oxide (NO) levels in patients with acromegaly. Total antioxidant capacity (TAC), catalase activity and glutathione concentration (GSH), as measures of antioxidative capacity, total oxidized glutathione (GSSG) and thiobarbituric acid reactive substances (TBARS), as indices of oxidative stress, and NO levels were assessed in 15 patients with acromegaly (age 55.4±10.5 years; 6 males) and 15 age- and sex-matched controls (age 58.4±8.1 years; 7 males). Active disease was present in 12 patients: 11 on current pharmacotherapy and 1 newly diagnosed. Three acromegalics were in remission after successful treatment. Acromegalics as compared with controls had significantly lower levels of catalase activity (8.2±5.8 vs. 51.3±29.1 mmol/ml/min, p<0.001), GSH (0.97±0.54 vs. 1.41±0.35 mmol/l, p=0.006), GSSG (0.27±0.19 vs. 2.04±1.32 mmol/l, p=0.002) and NO levels (6.0±3.1 vs. 43.0±29.8 mmol/l, p<0.001), but higher TBARS (16.3±8.9 vs. 10.1±10.8, nmol/ml, p=0.019). After adjustment for confounders, differences in catalase activity, NO levels and TBARS remained significant (p=0.004, p<0.001 and p=0.025, respectively). No association between IGF-I/GH and oxidative stress markers was noticed, except for a positive correlation between nadir GH and GSSG (r²=0.563, p=0.036). Acromegaly is associated with increased levels of oxidative stress coupled by diminished antioxidant capacity and endothelial dysfunction indicated by the presence of decreased NO levels.

Key words

acromegaly - oxidative stress - total antioxidant capacity - catalase - glutathione - nitric oxide

• References

• 1 Berg C, Petersenn S, Lahner H, Herrmann BL, Buchfelder M, Droste M, Stalla GK, Strasburger CJ, Roggenbuck U, Lehmann N, Moebus S, Jöckel KH, Möhlenkamp S, Erbel R, Saller B, Mann K. Investigative Group of the Heinz Nixdorf Recall Study and the German Pegvisomant Observational Study Board and Investigators . Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab 2010; 95: 3648-3656
• 2 Kondo T, Hirose M, Kageyama K. Roles of oxidative stress and redox regulation in atherosclerosis. J Atheroscler Thromb 2009; 16: 532-538
• 3 Andersson IJ, Johansson ME, Wickman A, Bohlooly-Y M, Klintland N, Caidahl K, Gustafsson M, Borén J, Gan LM, Bergström G. Endothelial dysfunction in growth hormone transgenic mice. Clin Sci (Lond) 2006; 110: 217-225
• 4 Ronconi V, Giacchetti G, Mariniello B, Camilletti A, Mantero F, Boscaro M, Vignini A, Mazzanti L. Reduced nitric oxide levels in acromegaly: cardiovascular implications. Blood Press 2005; 14: 227-232
• 5 Paisley AN, Izzard AS, Gemmell I, Cruickshank K, Trainer PJ, Heagerty AM. Small vessel remodeling and impaired endothelial-dependent dilatation in subcutaneous resistance arteries from patients with acromegaly. J Clin Endocrinol Metab 2009; 94: 1111-1117
• 6 Boero L, Cuniberti L, Magnani N, Manavela M, Yapur V, Bustos M, Rosso LG, Meroño T, Marziali L, Viale L, Evelson P, Negri G, Brites F. Increased oxidized low density lipoprotein associated with high ceruloplasmin activity in patients with active acromegaly. Clin Endocrinol (Oxf) 2010; 72: 654-660
• 7 Yarman S, Ozden TA, Gokkusu C. The evaluation of lipid peroxidation and acute effect of octreotide on lipid peroxidation in patients with active acromegaly. Clin Chim Acta 2003; 336: 45-48
• 8 Anagnostis P, Efstathiadou ZA, Polyzos SA, Adamidou F, Slavakis A, Sapranidis M, Litsas ID, Katergari S, Selalmatzidou D, Kita M. Acromegaly: presentation, morbidity and treatment outcomes at a single centre. Int J Clin Pract 2011; 65: 896-902
• 9 Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S. Acromegaly Consensus Group . A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010; 95: 3141-3148
• 10 Gougoura S, Nikolaidis MG, Kostaropoulos IA, Jamurtas AZ, Koukoulis G, Kouretas D. Increased oxidative stress indices in the blood of child swimmers. Eur J Appl Physiol 2007; 100: 235-239
• 11 Clayton RN. Cardiovascular function in acromegaly. Endocr Rev 2003; 24: 272-277
• 12 Muller G, Goettsch C, Morawietz H. Oxidative stress and endothelial dysfunction. Hamostaseologie 2007; 27: 5-12
• 13 Muller G, Morawietz H. NAD(P)H oxidase and endothelial dysfunction. Horm Metab Res 2009; 41: 152-158
• 14 Ignarro LJ. Physiology and pathophysiology of nitric oxide. Kidney Int 1996; 55 (Suppl) S2-S5
• 15 Markussis V, Beshyah SA, Fisher C, Parker KH, Nicolaides AN, Johnston DG. Abnormal carotid arterial wall dynamics in symptom-free hypopituitary adults. Eur J Endocrinol 1997; 136: 157-164
• 16 Meng D, Shi X, Jiang BH, Fang J. Insulin-like growth factor-I (IGF-I) induces epidermal growth factor receptor transactivation and cell proliferation through reactive oxygen species. Free Radic Biol Med 2007; 42: 1651-1660
• 17 Repetto M, Reides C, Gomez Carretero ML, Costa M, Griemberg G, Llesuy S. Oxidative stress in blood of HIV infected patients. Clin Chim Acta 1996; 255: 107-117
• 18 Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, Dimaraki E, Stavrou S, Vance ML, Hayden D, Klibanski A. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 2002; 87: 1692-1699
• 19 Delaroudis SP, Efstathiadou ZA, Koukoulis GN, Kita MD, Farmakiotis D, Dara OG, Goulis DG, Makedou A, Makris P, Slavakis A, Avramides AI. Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly. Clin Endocrinol (Oxf) 2008; 69: 279-284